![Breakthroughs that change patients’ lives]({"type":"image" , "src" : "/sda/112393/JournalAd-TACD-Pfizer-Leaderboard.jpg"})
References
- Kusano KF, Satomi K. Diagnosis and treatment of cardiac sarcoidosis. Heart. 2016;102:184–190.
- Houston BA, Park C, Mukherjee M. A diagnostic and therapeutic approach to arrhythmias in cardiac sarcoidosis. Curr Treat Options Cardiovasc Med. 2016;18:16.
- Birnie DH, Sauer WH, Judson MA. Consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart. 2016;102:411–414.
- Deng JC, Baughman RP, Lynch JP 3rd. Cardiac involvement in sarcoidosis. Semin Respir Crit Care Med. 2002;23:513–527.
- Schouver ED, Moceri P, Doyen D, et al. Early detection of cardiac involvement in sarcoidosis with 2-dimensional speckle-tracking echocardiography. Int J Cardiol. 2017;227:711–716.
- Hulten E, Agarwal V, Cahill M, et al. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2016;9:e005001.
- Ekström K, Lehtonen J, Hänninen H, et al. Magnetic resonance imaging as a predictor of survival free of life-threatening arrhythmias and transplantation in cardiac sarcoidosis. J Am Heart Assoc. 2016;5:pii: e003040.
- Nagai T, Nagano N, Sugano Y, et al. Effect of corticosteroid therapy on long-term clinical outcome and left ventricular function in patients with cardiac sarcoidosis. Circ J. 2015;79:1593–1600.
- Nagai T, Nagano N, Sugano Y, et al. Effect of discontinuation of prednisolone therapy on risk of cardiac mortality associated with worsening left ventricular dysfunction in cardiac sarcoidosis. Am J Cardiol. 2016;117:966–971.
- Mohsen A, Jimenez A, Hood RE, et al. Cardiac sarcoidosis: electrophysiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2014;25:171–176.
- Nagai S, Yokomatsu T, Tanizawa K, et al. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med. 2014;53:2761.
- Chiu CZ, Nakatani S, Zhang G, et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol. 2005;95:143–146.
- Yazaki Y, Isobe M, Hiroe M; Central Japan Heart Study Group, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006–1010.
- Kumar S, Barbhaiya C, Nagashima K, et al. Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol. 2015;8:87–93.
- Muser D, Santangeli P, Pathak RK, et al. Long-term outcomes of catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2016;9:e004333.
- Bandyopadhyay D, Sahoo D, Zein J, et al. Outcome of cardiac sarcoidosis after radiofrequency ablation and placement of AICD – a propensity matched analysis. Circ Arrhythm Electrophysiol. 2015;32:70–79.
- Willner JM, Viles-Gonzalez JF, Coffey JO, et al. Catheter ablation of atrial arrhythmias in cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2014;25:958–963.
- Perkel D, Czer LS, Morrissey RP, et al. Heart transplantation for end-stage heart failure due to cardiac sarcoidosis. Transplant Proc. 2013;45:2384–2386.
![Novo Nordisk – Driving change to defeat serious chronic diseases.]({"type":"image" , "src" : "/sda/112384/TACD_NovoNordisk.jpg"})
![Novartis. Your partner in Heart Failure & Atherosclerosis >>]({"type":"image" , "src" : "/sda/112381/JournalAd-TACD-Novartis-Skyscraper.jpg"})